Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation
Journal
Oncotarget
Journal Volume
8
Journal Issue
60
Pages
101832
Date Issued
2017-11-24
Abstract
To evaluate the impact of targeted agents in stage II-III rectal cancer undergoing neoadjuvant concurrent chemoradiation therapy (CCRT).
Subjects
CCRT; bevacizumab; cetuximab; rectal cancer; total mesorectal excision
SDGs
Other Subjects
bevacizumab; cetuximab; acne; adult; aged; alanine aminotransferase blood level; Article; cancer recurrence; cancer staging; cancer survival; chemoradiotherapy; digestive system perforation; disease course; disease free survival; drug efficacy; drug response; drug withdrawal; female; human; hypertension; laparoscopy; liver failure; liver toxicity; major clinical study; male; oncogene K ras; outcome assessment; paronychia; proteinuria; rectum cancer; retrospective study; survival rate; treatment outcome; tumor regression; upper gastrointestinal bleeding; very elderly; wound healing
Publisher
IMPACT JOURNALS LLC
Type
journal article